Even if Bcl-2 was over-expressed in the majority of SCLCs, several Bcl-2 inhibitors, such as G3139, did not improve any clinical outcome of patients with SCLC when they combined with chemotherapy [27]. The gene discussed is BCL2; the disease is small cell lung carcinoma.